When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Each month we present you with the latest featured study from the research teams at JAMA, Journal of the American Medical Association. Check out the video for intriguing…
Molecular analysis of biological samples is typically outsourced to well-equipped (and cost-intensive) laboratories. However, there are times when sample diagnosis and DNA sequencing is needed quickly, needed in…
John Lehr, CEO of the Parkinson’s Foundation, shares insights into how advances in research, education, and advocacy for patients with Parkinson’s (and the disease itself) is performed and…
Perfusion decellularization has recently been used to remove genetic material in pig organs, allowing them to be seeded with human stem cells in the hopes of securing a…
